Black Diamond Therapeutics, Inc.
BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The cā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.45
Price+0.75%
$0.02
1Y
Price
Market Cap
$139.486m
Small
Price/Earnings 3y Avg5y Avg
6.6x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$70m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
$21.498m
+130.9%
1y CAGR+52.0%
3y CAGR+45.8%
5y CAGREPS
$0.36
+128.4%
1y CAGR+62.1%
3y CAGR+53.4%
5y CAGRBook Value
$126.152m
$157.733m
Assets$31.581m
Liabilities$16.036m
DebtDebt to Assets
10.2%
0.9x
Debt to EBITDAFree Cash Flow
$21.346m
+134.3%
1y CAGR+54.2%
3y CAGR+44.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company